# V1 Empirics Check — qwen/qwen3.5-397b-a17b (Variant B)

**Model:** qwen/qwen3.5-397b-a17b
**Variant:** B
**Date:** 2026-03-14T11:00:47.135465

---

# Review of "The Resilient Drug Economy: EBT Implementation and the Limits of Payment-Infrastructure Disruption"

## 1. Idea Fidelity

This paper deviates significantly from the Original Idea Manifest (idea_0160). The Manifest explicitly proposed using **FBI Supplementary Homicide Report (SHR) drug-related circumstance codes** to isolate the drug-market channel of EBT crime reduction. It argued that SHR codes were the key innovation unavailable in standard UCR data and focused on **narcotics-related homicide** as the primary outcome. The submitted paper, however, substitutes **CDC drug poisoning mortality data** as the primary outcome. This shifts the economic question from *market disruption and violence* (the Manifest's focus) to *consumption and health overdoses*. Additionally, the Manifest proposed a data window starting in 1990 to capture pre-EBT trends (1990–1995), whereas the paper restricts the sample to 1999–2010 due to CDC data availability, thereby losing the early treatment variation (1996–1998) highlighted in the Manifest. While the identification strategy (CS-DiD) remains consistent, the core outcome and data window do not match the proposed design.

## 2. Summary

The paper estimates the causal effect of Electronic Benefit Transfer (EBT) implementation on drug poisoning mortality across US states (1999–2010). Using a Callaway–Sant'Anna difference-in-differences design, the authors find a precisely estimated null effect, suggesting that eliminating paper food stamps did not reduce drug overdoses. The authors interpret this as evidence that the drug economy's payment infrastructure is resilient to policy shocks, with participants substituting other cash sources for trafficked stamps.

## 3. Essential Points

The authors must address the following three critical issues to establish the paper's contribution:

1.  **Outcome Variable Mismatch:** The Manifest prioritized FBI SHR homicide data to test the *violence* channel of drug market disruption. The paper uses CDC mortality data, which tests the *consumption/health* channel. These are distinct mechanisms; reducing cash flow might reduce violence (competition for resources) without reducing overdoses (consumption levels). The authors must justify why this substitution was necessary and acknowledge that they are not testing the Manifest's primary hypothesis regarding market violence.
2.  **Truncated Treatment Variation:** By starting the sample in 1999, the paper excludes the earliest EBT adopters (1996–1998, e.g., Maryland, South Carolina). The Manifest emphasized this early variation as crucial for identification. The loss of these early cohorts reduces power and potentially biases the estimate if early adopters differed systematically in drug market structure from late adopters.
3.  **Opioid Epidemic Confounding:** The sample period (1999–2010) coincides with the onset of the prescription opioid epidemic. The paper attributes the null result partly to this secular trend but relies on year fixed effects to absorb it. Given that opioid exposure varied significantly by state (e.g., differential OxyContin marketing), state-specific trends in drug mortality may confound the EBT effect. The current design may not adequately separate EBT effects from heterogeneous opioid shocks.

## 4. Suggestions

The following recommendations aim to strengthen the paper's coherence, empirical rigor, and alignment with the proposed research agenda. These suggestions constitute the majority of the review content and should be prioritized in revision.

**Realigning with the Manifest's Outcome Strategy**
The Manifest identified FBI SHR drug-circumstance codes as the key innovation for isolating the drug-market channel. The paper's switch to CDC mortality data is a substantial departure that changes the interpretation of "drug market disruption." If SHR data is accessible (as confirmed in the Manifest's feasibility check), I strongly encourage the authors to incorporate it as a primary or secondary outcome. Homicide data directly reflects the *market friction* hypothesis (less cash leads to less violence over cash), whereas poisoning mortality reflects *consumption volume*. If SHR data is too noisy or unavailable, the authors must explicitly discuss this limitation in the Introduction and clarify that they are testing a *health* channel rather than the *violence* channel originally proposed. This distinction is vital for policy implications: EBT might reduce violence (Wright et al. 2017) without reducing overdoses, or vice versa.

**Addressing the Opioid Epidemic Confounding**
The discussion section correctly notes that the opioid epidemic transformed drug markets during the sample period. However, the empirical strategy relies heavily on year fixed effects to absorb this trend. This is insufficient because the opioid epidemic was not uniform; states varied dramatically in exposure to prescription opioids (e.g., Rust et al. 2020). To improve identification:
*   **Control for Opioid Supply:** Include state-year measures of prescription opioid volume (e.g., from CDC or DEA data) as a control variable. This helps separate the EBT effect from the opioid supply shock.
*   **Heterogeneity by Opioid Exposure:** Test whether the EBT effect differs in states with high vs. low initial opioid prescribing rates. If EBT disrupted street markets (cash-based) but the epidemic shifted markets to prescription-based (insurance/medical), the effect should be smaller in high-opioid states. This would support the "outcome timing" mechanism proposed in the discussion.
*   **Pre-EBT Trends:** The Manifest suggested 1990–1995 pre-periods. If CDC data does not allow this, consider using UCR drug arrest data (also mentioned in the Manifest) as a proxy for market activity that might have earlier coverage. This would help establish pre-trends before the opioid epidemic accelerated.

**Strengthening Mechanism Tests**
The Manifest proposed specific mechanism tests: (a) drug vs. non-drug violence decomposition, (b) drug arrest intensity, and (c) high-trafficking vs. low-trafficking state interaction. The paper currently relies on placebo outcomes (suicide, heart disease) which test general DiD validity but not the *drug market mechanism*.
*   **Trafficking Intensity:** The USDA estimated trafficking rates varied by state and declined with EBT. The authors should interact the EBT treatment with baseline state-level trafficking estimates (if available) or proxies for cash economy size (e.g., unbanked population rates). If the effect is larger in high-trafficking states, this supports the mechanism.
*   **Drug Arrests:** The Manifest suggested using UCR drug arrest data. Even if homicide data is unavailable, drug arrest rates could serve as a proxy for market activity intensity. A reduction in arrests (without reduction in deaths) might indicate market disruption; a null on both suggests resilience.
*   **Cash Proxies:** Consider adding controls for state-level cash usage or informal economy size. If EBT effects are concentrated in cash-dependent regions, this supports the payment-infrastructure hypothesis.

**Refining the Welfare Analysis**
The Manifest proposed a welfare calculation: VSL x prevented drug homicides vs. EBT implementation costs. The paper currently concludes with a qualitative policy implication. To enhance the "Insights" format contribution:
*   **Quantify the Null:** Explicitly calculate the implied welfare loss if policymakers expected a reduction that did not occur. For example, if policymakers anticipated a 10% reduction in drug deaths based trafficking estimates, what was the opportunity cost of implementing EBT for this purpose?
*   **Cost-Benefit Context:** Briefly reference the administrative costs of EBT implementation relative to the null benefit. This grounds the "resilience" finding in economic efficiency terms, making it more actionable for policymakers.

**Clarifying the Data Window Constraint**
The paper excludes 7 states adopting EBT in 1998–1999 from the CS-DiD sample because they lack pre-treatment data in the 1999-starting panel. This is a significant loss of variation.
*   **TWFE Inclusion:** Ensure these states are fully utilized in the TWFE specifications (as noted in the table notes) and discuss whether their exclusion from CS-DiD biases the ATT.
